Universe Pharmaceuticals INC
UPC · XNASCIK 1809616fmd_0WQE2PA9K9H8APJVA4KGTBNK40Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2018 to Sep 30, 2025, 11 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 33 | 31 | 48 | 40 | 32,309 | 23,024 | 17,859 |
| Cost of revenue | 20 | 17 | 23 | 18 | 21,994 | 16,953 | 11,558 |
| Net investment income | 0 | 0 | 0 | 0 | 0 | – | – |
| Gross profit | 13 | 14 | 25 | 22 | 10,315 | 6,072 | 6,301 |
| Research and development | 1 | 1 | 5 | 8 | 4,859 | 3,031 | 672 |
| Total operating expenses | 4 | 4 | 12 | 29 | 14,281 | 14,092 | 9,217 |
| Operating income | 10 | 10 | 14 | (7) | (3,966) | (8,020) | (2,916) |
| Interest expense | 0 | 0 | 0 | 0 | 190 | 305 | 289 |
| Other non-operating income (expense) | (0) | (0) | 0 | (0) | (361) | (101) | (756) |
| Income before taxes | 10 | 10 | 14 | (7) | (4,327) | (8,121) | (3,672) |
| Income tax expense | 2 | 3 | 2 | 1 | 2,254 | 607 | – |
| Net income from continuing operations | 8 | 8 | 11 | (8) | (6,581) | (8,727) | – |
| Net income | 8 | 8 | 11 | (8) | (6,581) | (8,727) | (3,672) |